Our commitment to make a difference in the lives of patients battling a variety of central nervous system (CNS) disorders and other uncommon conditions has yielded numerous company achievements. We are both proud of what Lundbeck has accomplished, and humbled by the recognition.
Highlights of our achievements include:
2011
- In October, Lundbeck announced the approval of ONFI™ (clobazam)
- The U.S. Food and Drug Administration (FDA) accepted Lundbeck’s submission of the new drug application (NDA) for clobazam
2010
- Lundbeck received the 2010 Corporate Award from the National Organization for Rare Disorders, a nonprofit organization dedicated to helping Americans with rare diseases. Lundbeck was bestowed the honor for our extensive efforts behind the approval and rapid launch of a product for a rare epilepsy.
- The Huntington's Disease Society of America - Northern California Chapter awarded Lundbeck its Humanitarian Award for the company’s dedication to the local Huntington’s disease community.
- The 2010 Corporate Star Award from the American Porphyria Foundation went to Lundbeck for its ongoing support of the Foundation and the patient community facing a complex, little-known rare disease.
2009
- The Huntington’s Disease Society of America recognized Lundbeck with the Marjorie Guthrie Leadership Award for the company’s steadfast commitment to the Huntington’s disease (HD) community and for making a meaningful contribution to patients and families impacted by HD across the country. This award is bestowed annually to a corporate leader who demonstrates the best in corporate philanthropy through humanitarian concern for the health and well-being of people.
- The Illinois Chapter of the Huntington’s Disease Society of America awarded Lundbeck with the Excellence in Corporate Achievement Award for making a meaningful contribution to the lives of people in the state of Illinois.
